Ontology highlight
ABSTRACT:
SUBMITTER: Cavaiola TS
PROVIDER: S-EPMC5905845 | biostudies-literature | 2018
REPOSITORIES: biostudies-literature
Cavaiola Tricia Santos TS Pettus Jeremy J
Diabetes, metabolic syndrome and obesity : targets and therapy 20180412
As the first cardiovascular (CV) outcome trial of a glucose-lowering agent to demonstrate a reduction in the risk of CV events in patients with type 2 diabetes mellitus (T2DM), the EMPAgliflozin Removal of Excess Glucose: Cardiovascular OUTCOME Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME<sup>®</sup>) trial, which investigated the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, has generated great interest among health care professionals. CV outcomes data fo ...[more]